US45579U1097
US45579U1097
Indivior Pharmaceuticals, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 4.23B EUR | 4.84B EUR | 3.72B EUR | 4.49B EUR |
Enterprise Value | 4.47B EUR | 5.13B EUR | 4.05B EUR | 4.64B EUR |
Valuation Multiples | ||||
Trailing P/E | 12.84x | 13.64x | 14.81x | 27.69x |
Forward P/E | 7.34x | -- | -- | -- |
Price to Sales | 3.18x | 3.63x | 2.88x | 4.61x |
Price to Book | -- | -- | -- | -- |
EV/Revenue | 3.36x | 3.85x | 3.14x | 4.77x |
EV/EBITDA | 7.76x | 11.22x | 10.84x | 20.18x |
Price to FCF (P/FCF) | 48.89x | -- | -- | -- |
EV/FCF | 51.68x | -- | -- | -- |
FCF Yield | 2.05% | -2.29% | -5.19% | -3.66% |